Drugs for Myelofibrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 279)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Panobinostat |
Approved, Investigational |
Phase 4 |
|
404950-80-7 |
6918837 |
Synonyms:
(2E)-N-HYDROXY-3-[4-({[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO}METHYL)PHENYL]ACRYLAMIDE
FARYDAK
Farydak®|LBH-589|LBH589
LBH 589
|
LBH589
LBH-589
PANOBINOSTAT
Panobinostatum
|
|
2 |
|
Lactitol |
Approved, Investigational |
Phase 4 |
|
585-86-4 |
157355 |
Synonyms:
4-O-beta-D-Galactopyranosyl-D-glucitol
4-O-β-D-Galactopyranosyl-D-glucitol
D-Lactitol
Emportal
Importal
Lactitol
|
Lactitolum
Neda lactiv importal
Oponaf
Pizensy
WURCS=2.0/2,2,1/[H2122H][a2112h-1b_1-5]/1-2/a4-b1
|
|
3 |
|
Histone Deacetylase Inhibitors |
|
Phase 4 |
|
|
|
4 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
5 |
|
Peginterferon alfa-2a |
Approved, Investigational |
Phase 3 |
|
198153-51-4 |
|
Synonyms:
PEGASYS
PEG-IFN alfa-2A
PEG-Interferon alfa-2A
PEGINTERFERON ALFA-2A
PEGYLATED IFN-ALPHA-2A
Pegylated Interfeaon alfa-2A
|
Pegylated interferon alfa-2a
Pegylated interferon alpha-2a
Pegylated-interferon alfa 2a
RO-258310000
ROFERON-A
|
|
6 |
|
Pomalidomide |
Approved |
Phase 3 |
|
19171-19-8 |
134780 |
Synonyms:
3-aminio-phthalimido-Glutarimide
3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide
3-Aminophthalimidoglutarimide
4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione
4-Aminothalidomide
CC 4047
CC-4047
CC-4047|IMID-3|Imnovid®|Pomalyst®
|
IMID-3
IMNOVID
Pomalidomida
POMALIDOMIDE
Pomalyst
S-3-amino-phthalimido-Glutarimide
S-3APG
|
|
7 |
|
Thalidomide |
Approved, Investigational, Withdrawn |
Phase 3 |
|
50-35-1 |
5426 |
Synonyms:
(+-)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
(+-)-THALIDOMIDE
(±)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
(±)-THALIDOMIDE
1,3-DIOXO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE
2,6-DIOXO-3-PHTHALIMIDOPIPERIDINE
3-PHTHALIMIDOGLUTARIMIDE
Algosediv
ALPHA-(N-PHTHALIMIDO)GLUTARIMIDE
ALPHA-N-PHTHALYLGLUTARAMIDE
alpha-Phthalimidoglutarimide
Asidon 3
Asmadion
Asmaval
Bonbrain
Bonbrrin
Calmore
Calmorex
Celgene brand OF thalidomide
Contergan
Corronarobetin
Distaval
Distaxal
Distoval
Ectiluran
Enterosediv
Gastrinide
Glupan
Glutanon
Grippex
Hippuzon
Imida-Lab
Imidan
Imidene
Isomin
K-17
Kedavon
Kevadon
Lulamin
N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
Neaufatin
Neo
Neosedyn
Neosydyn
Nerosedyn
Neufatin
Neurodyn
Neurosedin
Neurosedym
Neurosedyn
Nevrodyn
Nibrol
Noctosediv
Noxodyn
|
N-Phthalimidoglutamic acid imide
N-Phthaloylglutamimide
N-Phthalylglutamic acid imide
N-PHTHALYL-GLUTAMINSAEURE-IMID
NSC-527179
NSC-66847
Pangul
Pantosediv
Poly-Giron
Polygripan
Predni-Sediv
Pro-ban M
Profarmil
Psycholiquid
Psychotablets
Quetimid
Quietoplex
Sandormin
Sedalis
Sedalis sedi-lab
Sedimide
Sedin
Sedisperil
Sedoval
Shin-naito S
Shinnibrol
Sleepan
Slipro
Softenil
Softenon
Talargan
TALIDEX
TALIDOMIDA
Talimol
Talismol
Telagan
Telargan
Telargean
Tensival
Thaled
Thalidomide
THALIDOMIDUM
Thalidomine usp26
Thalin
Thalinette
Thalomid
Theophilcholine
Valgis
Valgraine
Yodomin
Α-(N-PHTHALIMIDO)GLUTARIMIDE
Α-N-PHTHALYLGLUTARAMIDE
Α-PHTHALIMIDOGLUTARIMIDE
|
|
8 |
|
Orange |
Approved |
Phase 3 |
|
|
|
9 |
|
Alemtuzumab |
Approved, Investigational |
Phase 2, Phase 3 |
|
216503-57-0 |
|
Synonyms:
ALEMTUZUMAB
ALEMTUZUMAB (GENETICAL RECOMBINATION)
CAMPATH
campath 1H|Campath®|campath-1H|Lemtrada®
CAMPATH MABCAMPATH
CAMPATH MABCAMPATH, LEMTRADA
|
CAMPATH-1H
GZ402673
GZ-402673
LDP-03
LEMTRADA
MABCAMPATH
|
|
10 |
|
Peginterferon alfa-2b |
Approved |
Phase 3 |
|
215647-85-1, 99210-65-8 |
|
Synonyms:
Interferon alfa-2b
Intron A
Peginterferon alfa-2b
PEGINTRON
|
PEG-INTRON
PegIntron®|Sylatron®
rIFN-alpha-2b
Unitron PEG
|
|
11 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 3 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
12 |
|
Mycophenolic acid |
Approved, Investigational |
Phase 3 |
|
24280-93-1 |
446541 |
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
68618
Acid, mycophenolic
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
Cellcept
ERL080
ERL-080
ERL-080|Myfortic® (mycophenolate sodium)
Melbex
Micofenolico acido
Mofetil hydrochloride, mycophenolate
Mofetil, mycophenolate
|
Mycophenoic acid
Mycophenolate
Mycophenolate mofetil
Mycophenolate mofetil hydrochloride
Mycophenolate sodium
Mycophenolate, sodium
MYCOPHENOLIC ACID
Mycophenolic acid morpholinoethyl ester
Mycophenolsaeure
Mycophenolsäure
Myfortic
NSC-129185
RS-61443 [AS MOFETIL]
Sodium mycophenolate
|
|
13 |
|
Lenograstim |
Approved, Investigational |
Phase 3 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
14 |
|
Apixaban |
Approved |
Phase 3 |
|
503612-47-3 |
10182969 |
Synonyms:
APIXABAN
APIXABÁN
Apixabanum
BMS 562247-01
|
BMS-562247
BMS-562247|Eliquis®
BMS-562247-01
Eliquis
|
|
15 |
|
Acetylsalicylic acid |
Approved, Vet_approved |
Phase 3 |
|
50-78-2 |
2244 |
Synonyms:
2-(ACETYLOXY)BENZOATE
2-(ACETYLOXY)benzoIC ACID
2-Acetoxybenzenecarboxylate
2-ACETOXYBENZENECARBOXYLIC ACID
2-ACETOXYBENZOATE
2-ACETOXYBENZOIC ACID
2-CARBOXYPHENYL ACETATE
8-HOUR BAYER
A.S.A.
A.S.A. Empirin
ACARD
ACENTERINE
Acesal
Acetal
ACETARD
ACETICYL
Acetilsalicilico
Acetilum acidulatum
Acetisal
ACETOL
ACETONYL
ACETOPHEN
Acetophen®|acetylsalicylic acid|Aspirin®
ACETOSAL
ACETOSALIC ACID
ACETOSALIN
Acetoxybenzoic acid
ACETYLIN
Acetylsal
ACETYLSALIC ACID
ACETYLSALICYLATE
ACETYLSALICYLIC ACID
Acetylsalicylsaeure
Acetylsalicylsaure
ACETYLSALICYLSÄURE
ACETYONYL
ACETYSAL
ACETYSALICYLIC ACID
Acid, acetylsalicylic
Acide 2-(acetyloxy)benzoique
ACIDE 2-(ACÉTYLOXY)BENZOÏQUE
Acide acetylsalicylique
ACIDE ACÉTYLSALICYLIQUE
Acido acetilsalicilico
ÁCIDO ACETILSALICÍLICO
Acido O-acetil-benzoico
ACIDUM ACETYLSALICYLICUM
Acimetten
Acisal
ACYLPYRIN
Adiro
ALKA RAPID
Aloxiprimum
ANADIN ALL NIGHT
ANGETTES 75
ASA
Asagran
ASATARD
Ascoden-30
Aspalon
Aspec
ASPERGUM
ASPIRDROPS
ASPIRIN
Aspirina
Aspirine
Aspro
ASPRO CLR
Asteric
Azetylsalizylsaeure
AZETYLSALIZYLSÄURE
BAY1019036
BAYER EXTRA STRENGTH
Bayer Extra Strength Aspirin For Migraine Pain
BENASPIR
Bialpirina
BIALPIRINIA
Bi-prin
BUFFERIN
CAPRIN
CARDIOASPIRINA
Cemirit
Claradin
Clariprin
Colfarit
Contrheuma retard
Coricidin
Crystar
DANAMEP
Decaten
Delgesic
Dispril
DISPRIN CV
|
DISPRIN DIRECT
Dolean pH 8
Duramax
DURLAZA
EASPRIN
ECM
ECOLEN
ECOTRIN
EMPIRIN
ENDOSPRIN
ENDYDOL
ENPRIN
Entericin
Enterophen
Enterosarein
Enterosarine
Entrophen
EQUI-PRIN
Extren
GENCARDIA
Globentyl
Globoid
Helicon
Idragin
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
LEVIUS
Magnecyl
MAX STRGH ASPRO CLR
MEASURIN
Micristin
MICROPIRIN EC
Neuronika
Novid
NSC-27223
NSC-406186
Nu-seals
NU-SEALS 300
NU-SEALS 600
NU-SEALS 75
Nu-seals aspirin
NU-SEALS CARDIO 75
O-(ACETYLOXY)BENZOATE
O-(ACETYLOXY)BENZOIC ACID
O-accetylsalicylic acid
O-ACETOXYBENZOATE
O-ACETOXYBENZOIC ACID
O-Acetylsalicylate
O-ACETYLSALICYLIC ACID
O-CARBOXYPHENYL ACETATE
O-Carboxyphenyl acetic acid
PAYNOCIL
PERSISTIN
PHARMACIN
Pirseal
PLATET
PLATET 300
Polopirin
POLOPIRYNA
POSTMI 300
POSTMI 75
PREMASPIN
RHEUMINTABLETTEN
RHODINE
Rhonal
Salacetin
SALCETOGEN
SALETIN
Salicylate acetate
SALICYLIC ACID ACETATE
Salicylic acid acetic acid
Salicylic acid, acetate
SALOSPIR
Solfrin
SOLPRIN
SOLPRIN ACID
SOLPYRON
Solupsan
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
Supac
TASPRIN
TEMPERAL
TOLDEX
TRIAMINICIN
Triple-sal
Vanquish
VAZALORE
Xaxa
Yasta
Zorprin
|
|
16 |
|
Luspatercept |
Approved, Investigational |
Phase 3 |
|
1373715-00-4 |
|
Synonyms:
|
17 |
|
Sodium citrate |
Approved, Investigational |
Phase 3 |
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
18 |
|
Rivaroxaban |
Approved |
Phase 3 |
|
366789-02-8 |
9875401 |
Synonyms:
BAY 59-7939
BAY 59-7939|Xarelto®
BAY59-7939
BAY-59-7939
|
JNJ39039039
JNJ-39039039
RIVAROXABAN
XARELTO
|
|
19 |
|
Danazol |
Approved |
Phase 3 |
|
17230-88-5 |
28417 |
Synonyms:
(17a)-Pregna-2,4-dien-20-yno[2,3-D]isoxazol-17-ol
17 alpha-Pregna-2,4-dien-20-yno[2,3-D] isoxazol-17 beta-ol
17a-Pregna-2,4-dien-20-yne-[2,3-D]isoxazole-17b-ol
17a-Pregna-2,4-dien-20-yno[2,3-D]isoxazol-17-ol
1-Ethynyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-10a,12a-dimethyl-1H-cyclopenta[7,8]phenanthro[3,2-D]isoxazol-1-ol
1H-Cyclopenta[7,8]phenanthro[3,2-D]isoxazole- pregna-2,4-dien-20-yno[2,3-D]isoxazol-17-ol deriv.
Alphapharm brand OF danazol
Antigen brand OF danazol
Azol
Bonzol
Chronogyn
Cyclomen
Danatrol
Danazant
DANAZOL
Danazol ratiopharm
Danazol-ratiopharm
Danazolum
|
Danocrine
Danocrine®
Danol
Danoval
Danovaol
Danzol
Kendrick brand OF danazol
Ladogal
Norciden
NSC-270916
Panacrine
Ratiopharm brand OF danazol
Sanofi brand OF danazol
Sanofi synthelabo brand OF danazol
Sanofi winthrop brand OF danazol
WIN-17757
Winobanin
|
|
20 |
|
D-Tyrosine |
Approved, Experimental, Investigational, Nutraceutical |
Phase 2, Phase 3 |
|
133585-56-5, 60-18-4, 556-02-5 |
1153 6057 |
Synonyms:
(-)-a-Amino-p-hydroxyhydrocinnamate
(-)-a-Amino-p-hydroxyhydrocinnamic acid
(-)-alpha-Amino-p-hydroxyhydrocinnamate
(-)-alpha-Amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamate
(−)-α-amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamic acid
(2S)-2-Amino-3-(4-hydroxyphenyl)propanoate
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
(2S)-2-AMINO-3-(4-HYDROXYPHENYL)PROPIONIC ACID
(2S)-2-AZANYL-3-(4-HYDROXYPHENYL)PROPANOIC ACID
(R)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(R)-3-(p-Hydroxyphenyl)alanine
(S)-(-)-Tyrosine
(S)-2-Amino-3-(p-hydroxyphenyl)propionate
(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(S)-3-(p-Hydroxyphenyl)alanine
(S)-a-Amino-4-hydroxybenzenepropanoate
(S)-a-Amino-4-hydroxy-benzenepropanoate
(S)-a-Amino-4-hydroxybenzenepropanoic acid
(S)-a-Amino-4-hydroxy-benzenepropanoic acid
(S)-alpha-Amino-4-hydroxybenzenepropanoate
(S)-alpha-Amino-4-hydroxy-benzenepropanoate
(S)-alpha-amino-4-Hydroxybenzenepropanoic acid
(S)-alpha-Amino-4-hydroxy-benzenepropanoic acid
(S)-Tyrosine
(S)-Α-amino-4-hydroxybenzenepropanoate
(S)-α-amino-4-hydroxybenzenepropanoic acid
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid
2-Amino-3-(4-hydroxyphenyl)propanoate
|
2-Amino-3-(4-hydroxyphenyl)propanoic acid
2-Amino-3-(p-hydroxyphenyl)propionate
2-Amino-3-(p-hydroxyphenyl)propionic acid
3-(4-Hydroxyphenyl)-L-alanine
3-(p-Hydroxyphenyl)alanine
4-hydroxy-L-phenylalanine
6-Hydroxysandoricin
Benzenepropanoate
Benzenepropanoic acid
D-Tyr
D-Tyrosin
FEMA NO. 3736
L Tyrosine
LEVODOPA IMPURITY, L-TYROSINE-
LEVODOPA RELATED COMPOUND L-TYROSINE
L-p-Tyrosine
L-Tyrosin
L-tyrosine
Methyl 2-[5,11-bis(acetyloxy)-13-(furan-3-yl)-16-hydroxy-6,6,8,12-tetramethyl-17-methylidene-15-oxo-2,14-dioxatetracyclo[7.7.1.0¹,¹².0³,⁸]heptadecan-7-yl]-2-hydroxyacetic acid
NSC-82624
Para tyrosine
Para-tyrosine
p-Tyrosine
Tirosina
Tyr
Tyrosin
Tyrosine
Tyrosine, L isomer
Tyrosine, L-isomer
Tyrosinum
Y
|
|
21 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
22 |
|
Imetelstat |
Investigational |
Phase 3 |
|
868169-64-6 |
|
Synonyms:
|
23 |
|
Angiogenesis Inhibitors |
|
Phase 3 |
|
|
|
24 |
|
Interferon alpha-2 |
|
Phase 3 |
|
|
|
25 |
|
Interferon-alpha |
|
Phase 3 |
|
|
|
26 |
|
Adjuvants, Immunologic |
|
Phase 3 |
|
|
|
27 |
|
Anti-Bacterial Agents |
|
Phase 3 |
|
|
|
28 |
|
Anti-Infective Agents |
|
Phase 3 |
|
|
|
29 |
|
Cyclooxygenase Inhibitors |
|
Phase 3 |
|
|
|
30 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 3 |
|
|
|
31 |
|
Androgens |
|
Phase 2, Phase 3 |
|
|
|
32 |
|
Analgesics, Non-Narcotic |
|
Phase 3 |
|
|
|
33 |
|
Anti-Inflammatory Agents |
|
Phase 3 |
|
|
|
34 |
|
Analgesics |
|
Phase 3 |
|
|
|
35 |
|
Antibiotics, Antitubercular |
|
Phase 3 |
|
|
|
36 |
|
Antitubercular Agents |
|
Phase 3 |
|
|
|
37 |
|
Fibrinolytic Agents |
|
Phase 3 |
|
|
|
38 |
|
Antipyretics |
|
Phase 3 |
|
|
|
39 |
|
Platelet Aggregation Inhibitors |
|
Phase 3 |
|
|
|
40 |
|
Anticoagulants |
|
Phase 3 |
|
|
|
41 |
|
Hematinics |
|
Phase 3 |
|
|
|
42 |
|
Motesanib diphosphate |
|
Phase 3 |
|
|
|
43 |
|
Citrate |
|
Phase 3 |
|
|
|
44 |
|
Estrogens |
|
Phase 3 |
|
|
|
45 |
|
Estrogen Receptor Antagonists |
|
Phase 3 |
|
|
|
46 |
|
Estrogen Antagonists |
|
Phase 3 |
|
|
|
47 |
|
Hepcidins |
|
Phase 3 |
|
|
|
48 |
|
Janus Kinase Inhibitors |
|
Phase 3 |
|
|
|
49 |
|
Everolimus |
Approved |
Phase 1, Phase 2 |
|
159351-69-6 |
70789204 6442177 |
Synonyms:
001, RAD
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-HYDROXYETHYL)RAPAMYCIN
Afinitor
AFINITOR DISPERZ
Afinitor®|Certican®|RAD-001|RAD001|rapamycin, 42-O-(2-hydroxyethyl)-|Zortress®
Certican
EVEROLIMUS
évérolimus
RAD 001
|
RAD 666
RAD, SDZ
RAD001
RAD-001
RAD-666
SDZ RAD
SDZ-RAD
VOTUBIA
ZORTRESS
|
|
50 |
|
Pembrolizumab |
Approved |
Phase 2 |
|
1374853-91-4 |
254741536 |
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
Interventional clinical trials:
(show top 50)
(show all 369)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A UK Open-label, Multicentre, Exploratory Phase II Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) |
Completed |
NCT01558739 |
Phase 4 |
INC424 |
2 |
Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies |
Recruiting |
NCT02386800 |
Phase 4 |
ruxolitinib;panobinostat |
3 |
A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis: a Multicenter, Prospective, Single-arm Clinical Study |
Recruiting |
NCT05447260 |
Phase 4 |
Ruxolitinib |
4 |
A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib |
Completed |
NCT02101268 |
Phase 3 |
Momelotinib;Best Available Therapy (BAT) |
5 |
A Multicenter, Open-label Clinical Study of the JAK Inhibitor Ruxolitinib (INC424) in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis |
Completed |
NCT02087059 |
Phase 3 |
Ruxolitinib |
6 |
INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation |
Completed |
NCT00799461 |
Phase 3 |
|
7 |
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) |
Completed |
NCT01969838 |
Phase 3 |
Momelotinib;Ruxolitinib;Placebo to match momelotinib;Placebo to match ruxolitinib |
8 |
A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies |
Completed |
NCT00438958 |
Phase 3 |
|
9 |
A Randomized Study of Ruxolitinib Tablets Compared to Best Available Therapy in Subjects With Primary Myelofibrosis, Post-Polycythemia Vera-Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis |
Completed |
NCT00934544 |
Phase 3 |
Ruxolitinib;Best Available Therapy (BAT) |
10 |
A Study to Provide Expanded Access of (Exjade®) Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload From Blood Transfusions Who Cannot Adequately be Treated With Other Locally Approved Iron Chelators |
Completed |
NCT00235391 |
Phase 3 |
Deferasirox |
11 |
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis |
Completed |
NCT00952289 |
Phase 3 |
Ruxolitinib;Placebo |
12 |
An Open-label, Multicenter, Expanded Access Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-essential Thrombocythemia Myelofibrosis (PET-MF). |
Completed |
NCT01493414 |
Phase 3 |
INC424 |
13 |
Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML) and Myelofibrosis (MF) |
Completed |
NCT01428635 |
Phase 2, Phase 3 |
Eltrombopag Olamine |
14 |
Danish Study of Low-dose Interferon Alpha Versus Hydroxyurea in the Treatment of Philadelphia Chromosome Negative (Ph-)Chronic Myeloid Neoplasms. |
Completed |
NCT01387763 |
Phase 3 |
PegIntron;Pegasys;Hydrea |
15 |
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of SAR302503 in Patients With Intermediate-2 or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly |
Completed |
NCT01437787 |
Phase 3 |
SAR302503;Placebo |
16 |
A Phase-3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy and Safety of Pomalidomide in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Red Blood Cell-Transfusion-Dependence |
Completed |
NCT01178281 |
Phase 3 |
Pomalidomide 0.5 mg;Placebo;Pomalidomide |
17 |
Randomized Study for Comparison of Reduced Intensity Conditioning Protocols Containing Either Thymoglobuline or Alemtuzumab in Patients Undergoing Allogeneic Transplant From Voluntary Unrelated Donors |
Completed |
NCT00354120 |
Phase 2, Phase 3 |
Alentuzumab;Globulina antilinfocitaria |
18 |
A Randomized, Double-blind, Double-simulated, Parallel-controlled, Multicenter Phase III Study Evaluating the Efficacy and Safety of Jaktinib Versus Hydroxycarbamide in Patients With Intermediate-2 or High-risk Myelofibrosis |
Recruiting |
NCT04617028 |
Phase 3 |
Jaktinib;Placebo to match Hydroxycarbamide;Hydroxycarbamide Tablets;Placebo to match Jaktinib |
19 |
A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy and Who Require Red Blood Cell Transfusions |
Recruiting |
NCT04717414 |
Phase 3 |
ACE-536 |
20 |
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor |
Recruiting |
NCT04576156 |
Phase 3 |
Imetelstat;Best Available Therapy (BAT) |
21 |
A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib |
Recruiting |
NCT04551053 |
Phase 3 |
parsaclisib;ruxolitinib;placebo |
22 |
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients |
Recruiting |
NCT04603495 |
Phase 3 |
Pelabresib;Ruxolitinib;Placebo |
23 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis |
Recruiting |
NCT04551066 |
Phase 3 |
parsaclisib;ruxolitinib;placebo |
24 |
A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment |
Recruiting |
NCT03662126 |
Phase 2, Phase 3 |
KRT-232;Best Available Therapy (BAT) |
25 |
A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials |
Recruiting |
NCT04064060 |
Phase 3 |
Luspatercept |
26 |
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/μL)(PACIFICA) |
Recruiting |
NCT03165734 |
Phase 3 |
Pacritinib;Physician's Choice medications |
27 |
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms |
Recruiting |
NCT05198960 |
Phase 3 |
Direct Oral Anticoagulants;Low-dose aspirin |
28 |
A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2) |
Recruiting |
NCT04468984 |
Phase 3 |
Navitoclax;Ruxolitinib;Best Available Therapy (BAT) |
29 |
A Phase 3, Multicenter, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Fedratinib Compared to Best Available Therapy (BAT) in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib |
Recruiting |
NCT03952039 |
Phase 3 |
FEDRATINIB;Best Available Therapy (BAT) |
30 |
Haploidentical Allogeneic Peripheral Blood Transplantation: Clinical Trial and Laboratory Correlates Examining Checkpoint Immune Regulators' Expression |
Recruiting |
NCT03480360 |
Phase 3 |
Cyclophosphamide;Fludarabine;Tacrolimus;cellcept;g-csf |
31 |
A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy and Safety Study of Fedratinib in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib |
Active, not recruiting |
NCT03755518 |
Phase 3 |
FEDRATINIB |
32 |
A Randomized, Double-blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic, Anemic Subjects With Primary Myelofibrosis (PMF), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Who Were Previously Treated With JAK Inhibitor Therapy |
Active, not recruiting |
NCT04173494 |
Phase 3 |
Momelotinib;Danazol;Placebo to match momelotinib;Placebo to match danazol |
33 |
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1) |
Active, not recruiting |
NCT04472598 |
Phase 3 |
Navitoclax;Ruxolitinib;Placebo for Navitoclax |
34 |
A Randomized, Double Blind, Placebo-controlled, Multicenter, Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations |
Terminated |
NCT02598297 |
Phase 3 |
Ruxolitinib;Ruxolitinib Placebo |
35 |
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis |
Terminated |
NCT02055781 |
Phase 3 |
Pacritinib;Best Available Therapy |
36 |
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis |
Terminated |
NCT01773187 |
Phase 3 |
Pacritinib;Best Available Therapy |
37 |
A Multicenter, Open Label Phase I/II Study of CEP-701 (Lestaurtinib) in Adults With Myelofibrosis |
Unknown status |
NCT00668421 |
Phase 1, Phase 2 |
CEP-701 (Lestaurtinib) |
38 |
A Phase I/II Open Label Study of LBH589, a Novel Histone Deacetylase Inhibitor (HDACi), in Patients With Primary Myelofibrosis (PMF) and Post-polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) |
Unknown status |
NCT01298934 |
Phase 1, Phase 2 |
LBH589 |
39 |
An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis |
Completed |
NCT00724334 |
Phase 1, Phase 2 |
SAR302503 (TG101348) |
40 |
A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), Or Post-Essential Thrombocythemia MF (Post-ET MF) |
Completed |
NCT01981850 |
Phase 2 |
Ruxolitinib |
41 |
Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells |
Completed |
NCT00795769 |
Phase 2 |
ondansetron |
42 |
A Phase 2 Open-Label, Dose-Ranging Study of the Efficacy and Safety of Orally Administered SAR302503 in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly |
Completed |
NCT01692366 |
Phase 2 |
SAR302503 |
43 |
Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Center Trial |
Completed |
NCT00397813 |
Phase 2 |
Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil |
44 |
A Phase I/II, Prospective, Open-Label Study to Determine the Safety and Efficacy of CC-4047 in Patients With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis® |
Completed |
NCT00669578 |
Phase 1, Phase 2 |
CC-4047 |
45 |
Evaluation of Ruxolitinib and Pracinostat Combination as a Therapy for Patients With Myelofibrosis |
Completed |
NCT02267278 |
Phase 2 |
Ruxolitinib;Pracinostat |
46 |
Phase 1/2 Randomized Trial Combination of Ruxolitinib and Peg-interferon Alpha-2a in Patients With Primary Myelofibrosis Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis |
Completed |
NCT02742324 |
Phase 1, Phase 2 |
Ruxolotinib;peg-IFN alpha -2a |
47 |
Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT) |
Completed |
NCT02065154 |
Phase 2 |
Cyclophosphamide |
48 |
A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens |
Completed |
NCT00489203 |
Phase 2 |
beclomethasone dipropionate;placebo;tacrolimus;methotrexate |
49 |
Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome Using Reduced Intensity Busulfan and Fludarabine Conditioning |
Completed |
NCT00475020 |
Phase 2 |
Busulfan;Fludarabine;Thymoglobulin (ATG) |
50 |
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis |
Completed |
NCT02718300 |
Phase 2 |
Parsaclisib;Ruxolitinib |
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Cell-based therapeutics:
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Myelofibrosis:
Embryonic/Adult Cultured Cells Related to Myelofibrosis:
|